A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

NCT06761677 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Due to challenges in recruiting eligible patients under the protocol.

Conditions

Relapsed or Refractory Lymphoma Including ENKL

Interventions

DRUG: Brincidofovir

Sponsor

SymBio Pharmaceuticals